Video: Study: Zestra(R) Improves Female & Partner Sexual Satisfaction



    
    Non-Prescription Zestra(R) Improves Female Arousal, Pleasure & Desire
    

    NEW YORK, Nov. 13 /CNW/ -- Zestra(R), the only women's intimacy product
clinically shown to quickly increase female sexual sensation, arousal and
pleasure, has released new findings from its latest research in women with the
most common sexual problems. These results show all-natural Zestra(R), a
topically applied solution, significantly improves sexual satisfaction of
women and their partners, in addition to overcoming difficulties women have
with desire, arousal and enjoying satisfying sexual experiences. About 43
percent of women in the United States suffer from female sexual dysfunction
(FSD).
    
    To view the Multimedia News Release, go to:
    http://www.prnewswire.com/mnr/zestra/30486/
    
    The leading women's intimacy product in the United States, Zestra stands
alone as the only non-hormonal, clinically studied intimacy product that
effectively addresses female sexual problems. The study findings are
particularly important to women, since the U.S. Food and Drug Administration
has required additional testing of potential hormone-based (testosterone)
drugs for desire because of concerns over safety. Research shows Zestra not
only improves the sexual experience of women who have sexual difficulties,
including those taking SSRI antidepressants, but also enhances the intimacy
experience for women without sexual difficulties.
    The Phase 3-type study evaluated the efficacy and safety of Zestra(R),
compared to placebo oil in 256 women diagnosed with acquired mixed
interest/desire/arousal/orgasm disorders in conditions of home use in
conjunction with sexual activities. "Zestra was well-tolerated, and no serious
adverse events (SAEs) were associated with study participants' use of the
product," David M. Ferguson, PhD, MD, FACCP, the study's clinical director,
said.
    Dr. Ferguson, a contributor to the development of the Female Sexual
Function Index (FSFI), organized and directed the first
industry/academic/regulatory advisory collaborative workshop on female sexual
dysfunction in 1998. This workshop served as a catalyst for establishment of
the FDA's clinical guidelines for research and development of potential
prescription drugs for female sexual dysfunction.
    "This second clinical trial further demonstrates the significant,
positive effects non-prescription Zestra has on female sexual difficulties,"
Dr. Ferguson said. "An unexpected -- and gratifying-- finding was the
significant effect Zestra has on increasing female desire and also, increasing
the perception of satisfaction by their partner."
    Non-prescription Zestra(R), a patented formula that is the result of
seven years of research and clinical testing, is hormone free and does not use
potentially harmful synthetic chemicals or parabens. Parabens, which the U.S.
Environmental Protection Agency views as disrupters of the body's endocrine
system, have been linked to breast cancer, lowered sperm counts and allergic
reactions. Parabens, many of which are banned in Europe, are ingredients found
in most personal lubricants and "warming liquids" that are on retail shelves,
but are not in Zestra(R).
    Numerous books on women's sexual health recommend the use of Zestra. Non-
prescription Zestra is available at 40,000 retailers (leading drugstores,
supermarkets and mass retailers).
    About Zestra(R) Feminine Arousal Fluid (U.S. Patent 6,737,084; EP Patent
EP1328281)
    Zestra Laboratories, Inc., a specialty consumer health products company,
is developer and manufacturer of Zestra(R) Feminine Arousal Fluid, a patented,
all-natural formulation of two botanical oils and two extracts. It is the only
consumer product clinically shown to quickly increase female sexual sensation,
arousal, pleasure and desire. Non-prescription Zestra(R) does not contain
potentially harmful synthetics, hormones or parabens.
    Zestra(R), the result of seven years of research and clinical testing,
has shown to be effective in both Phase II-type and Phase III-type,
FDA-quality studies for women who have sexual difficulties, including those
taking SSRI antidepressants, and to enhance the intimacy experience for women
without sexual difficulties. In 2006, Zestra(R) became the leading women's
intimacy product sold in the United States. It is available at about 40,000
pharmacies and select supermarkets, including those in Canada, the United
Kingdom, China, Mexico, and 11 other countries. For more information, visit
www.zestra.com.
    Please contact Kristie Bohm Byrum for interviews with experts from Kinsey
Institute, Columbia University and other leading institutions who can discuss
the study and Zestra(R).

    Contact Information

    
     Kristie Bohm Byrum, APR
     Zestra/Byrum Innovation Group
     864.242.1102
     kristiebyrum@byruminnovation.com
    




For further information:

For further information: Kristie Bohm Byrum, APR of Zestra-Byrum 
Innovation Group, +1-864-242-1102, kristiebyrum@byruminnovation.com Web Site:
http://www.zestra.com

Organization Profile

ZESTRA LABORATORIES

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890